AAPL 244.6 1.2711% MSFT 408.43 -0.514% NVDA 138.85 2.6314% GOOGL 185.23 -0.4889% GOOG 186.87 -0.5376% AMZN 228.68 -0.7336% META 736.67 1.1132% AVGO 233.04 -1.1705% LLY 844.27 -2.9976% TSLA 355.84 -0.0281% TSM 203.9 1.0256% V 353.81 -0.5118% JPM 276.59 0.0977% UNH 523.51 -1.444% NVO 77.87 -1.2178% WMT 104.04 -0.9614% LVMUY 149.83 0.7193% XOM 108.24 0.1017% LVMHF 752.0 1.2059% MA 564.76 -0.2737%
Last update at 2025-02-14T21:00:00Z
HALO Gears Up to Report Q4 Earnings: Here's What You Should Know
Thu 13 Feb 25, 04:01 PMHere's How Much You'd Have If You Invested $1000 in Halozyme Therapeutics a Decade Ago
Wed 12 Feb 25, 01:30 PMHalozyme Therapeutics, Inc. (HALO): A Cheap Biotech Stock to Invest In Now
Wed 12 Feb 25, 11:13 AMBeiGene Stock Meets 80-Plus RS Rating Benchmark
Wed 15 Jan 25, 08:44 PMZacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines
Wed 15 Jan 25, 08:48 AMBridgeBio Pharma Stock Earns 87 RS Rating
Tue 14 Jan 25, 08:30 PM5 Biotech Stocks Worth Adding to Your Portfolio in 2025
Tue 14 Jan 25, 03:02 PMPCRX Stock Rises 11% on Upbeat Q4 Preliminary Product Sales
Mon 13 Jan 25, 04:43 PMHalozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why
Fri 10 Jan 25, 05:45 PMSANA Stock Surges 152% in a Week on Upbeat Initial Diabetes Study Data
Fri 10 Jan 25, 03:16 PMBreakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Income before tax | 248.92M | 248.52M | 129.30M | -72.25100M | -79.79300M |
Minority interest | - | - | - | - | - |
Net income | 202.13M | 402.71M | 129.09M | -72.24000M | -80.33000M |
Selling general administrative | 143.53M | 50.32M | 45.74M | 77.25M | 60.80M |
Selling and marketing expenses | - | - | - | - | - |
Gross profit | 520.81M | 361.90M | 224.23M | 150.45M | 141.73M |
Reconciled depreciation | 49.64M | 3.00M | 3.28M | 4.07M | 2.39M |
Ebit | 267.53M | 272.90M | 140.97M | -71.67800M | -71.71800M |
Ebitda | 310.68M | 275.90M | 144.25M | -67.61000M | -69.33000M |
Depreciation and amortization | 43.15M | 3.00M | 3.28M | 4.07M | 2.39M |
Non operating income net other | -1.66600M | -19.85800M | 5.42M | 6.99M | 7.58M |
Operating income | 267.53M | 275.90M | 144.25M | -67.61000M | -69.33000M |
Other operating expenses | 392.58M | 167.41M | 123.34M | 263.60M | 221.19M |
Interest expense | 16.95M | 7.53M | 20.38M | 11.63M | 18.04M |
Tax provision | 46.79M | -154.19200M | 0.22M | -0.01100M | 0.54M |
Interest income | - | - | - | 4.64M | 10.46M |
Net interest income | -16.94700M | -7.52600M | -20.37800M | -11.62700M | -18.04100M |
Extraordinary items | - | - | - | - | - |
Non recurring | - | - | - | - | - |
Other items | - | - | - | - | - |
Income tax expense | 46.79M | -154.19200M | 0.22M | -0.01100M | 0.54M |
Total revenue | 660.12M | 443.31M | 267.59M | 195.99M | 151.86M |
Total operating expenses | 253.28M | 86.00M | 79.97M | 218.06M | 211.06M |
Cost of revenue | 139.30M | 81.41M | 43.37M | 45.55M | 10.14M |
Total other income expense net | -18.61300M | -27.38400M | -14.95300M | -4.64100M | 7.58M |
Discontinued operations | - | - | - | - | - |
Net income from continuing ops | 202.13M | 402.71M | 129.09M | -72.24000M | -80.33000M |
Net income applicable to common shares | 202.13M | 402.71M | 129.09M | -72.24000M | -80.33000M |
Preferred stock and other adjustments | - | - | - | - | - |
Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
Total assets | 1733.27M | 1841.51M | 1104.43M | 579.92M | 565.87M |
Intangible assets | 472.88M | 546.65M | - | - | - |
Earning assets | - | - | - | - | - |
Other current assets | 48.61M | 45.02M | 40.48M | 28.27M | 33.37M |
Total liab | 1649.46M | 1671.71M | 907.48M | 428.88M | 474.11M |
Total stockholder equity | 83.81M | 169.80M | 196.95M | 151.05M | 91.77M |